安罗替尼治疗晚期恶性肿瘤的药物经济学评价现状OA

Objective To systematically evaluate the current status of pharmacoeconomic evaluation of Anlotinib in the treatment of advanced malignant tumors.Methods A computer system was used to search for publicly published pharmacoeconomic evaluation studies on the treatment of advanced malignant tumors with Anlotinib in the Chinese Journal Full Text Database,Wanfang Data Knowledge Service Platform,Chinese Journal Full Text Database,PubMed,Embase,The Cochrane Library.Researchers independently screen literature,extract discount rates,relevant research methods,sensitivity analysis,and other data from the literature,and analyze and summarize them.Results After preliminary search,15 articles were obtained,and after layer by layer screening,a total of 5 articles were included.Among them,3 studies focused on non-small cell lung cancer,and the results showed that Anlotinib was not cost-effective.2 studies focused on small cell lung cancer,and the results showed that Anlotinib was cost-effective.Three out of five studies used a discount rate of 3%,while the other two studies used a discount rate of 5%.Among the five studies included,one used the Markov model for cost-effectiveness analysis,while the other four used the Markov model for cost-effectiveness analysis.The five included studies all used both single factor sensitivity analysis and probability sensitivity analysis.Conclusion Anlotinib is not economically effective in treating non-small cell lung cancer,but economically effective in treating small cell lung cancer.There is relatively little research on the economic evaluation of Anlotinib drugs in China;There is no unified standard for selecting research perspectives and discount rates;The types of diseases covered by the research institute are relatively single;The selection of research perspectives does not match the determination of costs.